Altamira Therapeutics receives Nasdaq non-compliance letter

Stock Information for Altamira Therapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Altamira Therapeutics Ltd.

Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
Altamira Therapeutics Provides Update on Nasdaq Listing
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.